- Conditions
- Pelvic Floor Disorders, Sexual Dysfunction, Incontinence, Pelvic Organ Prolapse
- Interventions
- Survey
- Other
- Lead sponsor
- International Urogynecological Society
- Other
- Eligibility
- 18 Years to 100 Years · Female only
- Enrollment
- 877 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2012
- U.S. locations
- 9
- States / cities
- San Diego, California • Evanston, Illinois • Minneapolis, Minnesota + 5 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 49–72
of 161
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Hypoactive Sexual Desire Disorder, Sexual Dysfunction, Female Sexual Dysfunction
- Interventions
- mindfulness-based multicomponent intervention, general health education group
- Behavioral
- Lead sponsor
- University of Pittsburgh
- Other
- Eligibility
- 50 Years and older · Female only
- Enrollment
- 62 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Anxiety Disorder, Cervical Cancer, Endometrial Cancer, Female Reproductive Cancer, Gestational Trophoblastic Tumor, Ovarian Epithelial Cancer, Ovarian Germ Cell Tumor, Sexual Dysfunction, Uterine Sarcoma, Vaginal Cancer, Vulvar Cancer
- Interventions
- informational intervention, counseling intervention, questionnaire administration
- Other
- Lead sponsor
- University of Wisconsin, Madison
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin
- Conditions
- Menopause, Sexual Dysfunction, Libido Disorder, Testosterone Deficiency
- Interventions
- Transdermal testosterone gel, Transdermal placebo gel
- Other
- Lead sponsor
- The University of Texas Health Science Center, Houston
- Other
- Eligibility
- 40 Years to 65 Years · Female only
- Enrollment
- 150 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2027 – 2028
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Lower Urinary Tract Symptoms, Colorectal Disorders
- Interventions
- Not listed
- Lead sponsor
- University of California, Irvine
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 1
- States / cities
- Orange, California
- Conditions
- Hypoactive Sexual Desire Disorder (DSM-IV-TR Defined), Sexual Interest/Arousal Disorder (DSM-5 Defined)
- Interventions
- bupropion, Lorexys low-dose, Lorexys moderate-dose
- Drug
- Lead sponsor
- S1 Biopharma, Inc.
- Industry
- Eligibility
- 25 Years to 50 Years · Female only
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 2
- States / cities
- Beachwood, Ohio • Cincinnati, Ohio
- Conditions
- Sexual Dysfunction, Depression
- Interventions
- sildenafil
- Drug
- Lead sponsor
- University of New Mexico
- Other
- Eligibility
- 18 Years to 50 Years · Female only
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2005
- U.S. locations
- 1
- States / cities
- Albuquerque, New Mexico
- Conditions
- Female Sexual Dysfunction
- Interventions
- Low dose testosterone nasal gel, single dose, Medium dose testosterone nasal gel, single dose, High dose testosterone nasal gel, single dose, Medium dose testosterone nasal gel, multiple dose
- Drug
- Lead sponsor
- Acerus Pharmaceuticals Corporation
- Industry
- Eligibility
- 18 Years to 40 Years · Female only
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2012
- U.S. locations
- 1
- States / cities
- Austin, Texas
- Conditions
- Spinal Muscular Atrophy, Fragile X Syndrome, Fragile X - Premutation, Duchenne Muscular Dystrophy, Hyperinsulinemic Hypoglycemia, Familial 1, Diabetes Mellitus, Adrenoleukodystrophy, Neonatal, Medium-chain Acyl-CoA Dehydrogenase Deficiency, Very Long Chain Acyl Coa Dehydrogenase Deficiency, Beta-ketothiolase Deficiency, Severe Combined Immunodeficiency Due to Adenosine Deaminase Deficiency, Primary Hyperoxaluria Type 1, Congenital Bile Acid Synthesis Defect Type 2, Pyridoxine-Dependent Epilepsy, Hereditary Fructose Intolerance, Hypophosphatasia, Hyperargininemia, Mucopolysaccharidosis Type 6, Argininosuccinic Aciduria, Citrullinemia, Type I, Wilson Disease, Maple Syrup Urine Disease, Type 1A, Maple Syrup Urine Disease, Type 1B, Biotinidase Deficiency, Neonatal Severe Primary Hyperparathyroidism, Intrinsic Factor Deficiency, Usher Syndrome Type 1D/F Digenic (Diagnosis), Cystic Fibrosis, Stickler Syndrome Type 2, Stickler Syndrome Type 1, Alport Syndrome, Autosomal Recessive, Alport Syndrome, X-Linked, Carbamoyl Phosphate Synthetase I Deficiency Disease, Carnitine Palmitoyl Transferase 1A Deficiency, Carnitine Palmitoyltransferase II Deficiency, Cystinosis, Chronic Granulomatous Disease, Cerebrotendinous Xanthomatoses, Maple Syrup Urine Disease, Type 2, Severe Combined Immunodeficiency Due to DCLRE1C Deficiency, Thyroid Dyshormonogenesis 6, Thyroid Dyshormonogenesis 5, Supravalvar Aortic Stenosis, Factor X Deficiency, Hemophilia A, Hemophilia B, Tyrosinemia, Type I, Fructose 1,6 Bisphosphatase Deficiency, Glycogen Storage Disease Type I, G6PD Deficiency, Glycogen Storage Disease II, Galactokinase Deficiency, Mucopolysaccharidosis Type IV A, Galactosemias, Guanidinoacetate Methyltransferase Deficiency, Agat Deficiency, Glutaryl-CoA Dehydrogenase Deficiency, Gtp Cyclohydrolase I Deficiency, Hyperinsulinism-Hyperammonemia Syndrome, Primary Hyperoxaluria Type 2, 3-Hydroxyacyl-CoA Dehydrogenase Deficiency, Long-chain 3-hydroxyacyl-CoA Dehydrogenase Deficiency, Mitochondrial Trifunctional Protein Deficiency, Sickle Cell Disease, Beta-Thalassemia, Holocarboxylase Synthetase Deficiency, 3-Hydroxy-3-Methylglutaric Aciduria, Primary Hyperoxaluria Type 3, Hermansky-Pudlak Syndrome 1, Hermansky-Pudlak Syndrome 4, Apparent Mineralocorticoid Excess, HSDB, CBAS1, Mucopolysaccharidosis Type 2, Mucopolysaccharidosis Type 1, Severe Combined Immunodeficiency, X Linked, Severe Combined Immunodeficiency Due to IL-7Ralpha Deficiency, Diabetes Mellitus, Permanent Neonatal, Isovaleric Acidemia, Severe Combined Immunodeficiency T-Cell Negative B-Cell Positive Due to Janus Kinase-3 Deficiency (Disorder), Jervell and Lange-Nielsen Syndrome 2, Hyperinsulinemic Hypoglycemia, Familial, 2, Diabetes Mellitus, Permanent Neonatal, With Neurologic Features, Jervell and Lange-Nielsen Syndrome 1, Lysosomal Acid Lipase Deficiency, CblF, 3-Methylcrotonyl CoA Carboxylase 1 Deficiency, 3-Methylcrotonyl CoA Carboxylase 2 Deficiency, Waardenburg Syndrome Type 2A, Methylmalonic Aciduria cblA Type, Methylmalonic Aciduria cblB Type, Methylmalonic Aciduria and Homocystinuria Type cblC, MAHCD, Methylmalonic Aciduria Due to Methylmalonyl-CoA Mutase Deficiency, Congenital Disorder of Glycosylation Type 1B, Mthfr Deficiency, Methylcobalamin Deficiency Type Cbl G (Disorder), Methylcobalamin Deficiency Type cblE, Usher Syndrome, Type 1B, N-acetylglutamate Synthase Deficiency, Ornithine Transcarbamylase Deficiency, Phenylketonurias, Waardenburg Syndrome Type 1, Congenital Hypothyroidism, Propionic Acidemia, Usher Syndrome, Type 1F, Pancreatic Agenesis 1, Hereditary Hypophosphatemic Rickets, Glycogen Storage Disease IXB, Glycogen Storage Disease IXC, MOWS, Epilepsy, Early-Onset, Vitamin B6-Dependent, Pyridoxal Phosphate-Responsive Seizures, Pituitary Hormone Deficiency, Combined, 1, Ptsd, Dihydropteridine Reductase Deficiency, Severe Combined Immunodeficiency Due to RAG1 Deficiency, Severe Combined Immunodeficiency Due to RAG2 Deficiency, Retinoblastoma, Multiple Endocrine Neoplasia Type 2B, Pseudohypoaldosteronism, Type I, Liddle Syndrome, Biotin-Responsive Basal Ganglia Disease, SCD, DIAR1, GSD1C, Acrodermatitis Enteropathica, Thyroid Dyshormonogenesis 1, Riboflavin Transporter Deficiency, Waardenburg Syndrome, Type 2E, SRD, Congenital Lipoid Adrenal Hyperplasia Due to STAR Deficiency, Barth Syndrome, Adrenocorticotropic Hormone Deficiency, Transcobalamin II Deficiency, Thyroid Dyshormonogenesis 3, Segawa Syndrome, Autosomal Recessive, Autosomal Recessive Nonsyndromic Hearing Loss, Thyroid Dyshormonogenesis 2A, Congenital Isolated Thyroid Stimulating Hormone Deficiency, Hypothyroidism Due to TSH Receptor Mutations, Usher Syndrome Type 1C, Usher Syndrome Type 1G (Diagnosis), Von Willebrand Disease, Type 3, Combined Immunodeficiency Due to ZAP70 Deficiency, Adenine Phosphoribosyltransferase Deficiency, Metachromatic Leukodystrophy, Canavan Disease, Menkes Disease, Carbonic Anhydrase VA Deficiency, Developmental and Epileptic Encephalopathy 2, 17 Alpha-Hydroxylase Deficiency, Smith-Lemli-Opitz Syndrome, Krabbe Disease, Glutathione Synthetase Deficiency, Mucopolysaccharidosis Type 7, Rett Syndrome, Molybdenum Cofactor Deficiency, Type A, Niemann-Pick Disease, Type C1, Niemann-Pick Disease Type C2, Ornithine Aminotransferase Deficiency, 3-Phosphoglycerate Dehydrogenase Deficiency, Leber Congenital Amaurosis 2, Dravet Syndrome, Mucopolysaccharidosis Type 3 A, Ornithine Translocase Deficiency, Carnitine-acylcarnitine Translocase Deficiency, Glucose Transporter Type 1 Deficiency Syndrome, Creatine Transporter Deficiency, Niemann-Pick Disease Type A, Pitt Hopkins Syndrome, Tuberous Sclerosis 1, Tuberous Sclerosis 2, Ataxia With Isolated Vitamin E Deficiency, Angelman Syndrome, Prader-Willi Syndrome, Homocystinuria, Permanent Neonatal Diabetes Mellitus, Transient Neonatal Diabetes Mellitus, Factor VII Deficiency, Glycogen Storage Disease Type IXA1, Glycogen Storage Disease, Type IXA2, Glycogen Storage Disease IC, Glycogen Storage Disease Type IB, Central Hypoventilation Syndrome With or Without Hirschsprung Disease
- Interventions
- Confirmatory Testing
- Diagnostic Test
- Lead sponsor
- RTI International
- Other
- Eligibility
- 1 Day to 31 Days
- Enrollment
- 30,000 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2026
- U.S. locations
- 1
- States / cities
- Research Triangle Park, North Carolina
- Conditions
- Female Patients With High Tone Pelvic Floor Dysfunction
- Interventions
- Vaginal Diazepam Suppository, Placebo Suppository
- Drug
- Lead sponsor
- TriHealth Inc.
- Other
- Eligibility
- 18 Years to 65 Years · Female only
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
- Conditions
- Stress Urinary Incontinence, Sexual Dysfunction
- Interventions
- Pelvic floor exerciser
- Device
- Lead sponsor
- Lelo Inc.
- Industry
- Eligibility
- 20 Years to 69 Years · Female only
- Enrollment
- 93 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 1
- States / cities
- Phoenix, Arizona
- Conditions
- Vaginal Infection, Vaginal Discharge, Vaginosis, Sexual Dysfunction
- Interventions
- LiviWell Postcoital Vaginal Insert
- Device
- Lead sponsor
- Atlantic Health System
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 1,000 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- Mountain Lakes, New Jersey
- Conditions
- Spinal Cord Injury, Sexual Dysfunction Female
- Interventions
- Vibratory genital nerve stimulation
- Device
- Lead sponsor
- Samuel Cramer
- Other
- Eligibility
- 18 Years to 65 Years · Female only
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Dyspareunia
- Interventions
- Estradiol, Imvexxy, Placebo
- Drug
- Lead sponsor
- Teva Pharmaceuticals USA
- Industry
- Eligibility
- 40 Years to 75 Years · Female only
- Enrollment
- 1,050 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2024
- U.S. locations
- 42
- States / cities
- Birmingham, Alabama • Chandler, Arizona • Sacramento, California + 36 more
- Conditions
- Vaginal Atrophy, Genitourinary System; Disorder, Female, Vaginal Abnormality, Sexual Dysfunction, Sexual Problem
- Interventions
- Viveve®
- Device
- Lead sponsor
- W. Grant Stevens, MD
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 10 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2020
- U.S. locations
- 1
- States / cities
- Marina del Rey, California
- Conditions
- Bladder Pain Syndrome, Female Sexual Dysfunction
- Interventions
- Onabotulinum toxin A, Conservative management (dietary and behavioral)
- Drug · Behavioral
- Lead sponsor
- Walter Reed National Military Medical Center
- Federal
- Eligibility
- 18 Years to 99 Years · Female only
- Enrollment
- 159 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Sexual Function
- Interventions
- Perineorrhaphy
- Procedure
- Lead sponsor
- Wake Forest University Health Sciences
- Other
- Eligibility
- 19 Years to 105 Years · Female only
- Enrollment
- 44 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2017
- U.S. locations
- 2
- States / cities
- Birmingham, Alabama • Winston-Salem, North Carolina
- Conditions
- Female Sexual Dysfunction, Female Sexual Dysfunction Due to Physical Condition
- Interventions
- Transcutaneous electrical nerve stimulation - Tibial Nerve, Transcutaneous electrical nerve stimulation - Genital Nerve, Neutral and Erotic Film Clip Alternation
- Device · Behavioral
- Lead sponsor
- University of Michigan
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 15 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2024
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Obstetric; Injury Pelvic Floor, Sexual Dysfunction, Anal Incontinence, Urinary Incontinence
- Interventions
- Estradiol 0.01% Vag Cream, Placebo vaginal cream
- Drug
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 38 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
- Conditions
- Post-operative Dyspareunia
- Interventions
- Dilator use
- Behavioral
- Lead sponsor
- Medstar Health Research Institute
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 1
- States / cities
- Washington D.C., District of Columbia
- Conditions
- Female Sexual Dysfunction, Multiple Sclerosis, Spinal Cord Injury
- Interventions
- Sympathetic manipulation on sexual arousal in women
- Procedure
- Lead sponsor
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
- NIH
- Eligibility
- 18 Years to 55 Years · Female only
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2005
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
- Conditions
- Orgasmic Disorder
- Interventions
- Wellbutrin XL
- Drug
- Lead sponsor
- Segraves, R., T., M.D., Ph.D.
- Other
- Eligibility
- 20 Years to 50 Years · Female only
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2007
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Colorectal Cancer (Diagnosis), Anal Cancer, Sexual Dysfunction Female
- Interventions
- Mind-Body Group Intervention, Enhanced Usual Care Control (EUCC)
- Behavioral
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Women's Health: Neoplasm of Breast, Menopause, Premature, Body Image, Sexual Dysfunction, Cancer, Breast
- Interventions
- EMBRACE (Empowerment through Mind and Body Reclamation After Cancer Experience)
- Behavioral
- Lead sponsor
- University of Arkansas
- Other
- Eligibility
- 18 Years to 50 Years · Female only
- Enrollment
- 43 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- Little Rock, Arkansas